Morphoea (Localized Scleroderma)

Harper's Textbook of Pediatric Dermatology: Third Edition

Volumn 2, Issue , 2011, Pages 1-13

  Weibel, Lisa ^a   Harper, John ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

Blaschko's lines; Corticosteroids; Fibrosis; Localized,scleroderma; Methotrexate; Morphoea en coup de sabre; Parry Romberg syndrome; Sclerosis; Thermography

Indexed keywords

EID: 84886552925     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444345384.ch173     Document Type: Chapter

References (124)

1. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068-76.
2. Zulian F, Athreya BH, Laxer R et al. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology 2006; 45: 614-20.
3. Laxer RM, Zulian F. Localized scleroderma. Curr Opin Rheumatol 2006; 18: 606-13.
4. Zulian F, Vallongo C, Woo P et al. Localized scleroderma in childhood is not just a skin disease. Arthr Rheum 2005; 52: 2873-81.
5. Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol 2008; 59: 385-96.
6. Murray KJ, Laxer RM. Scleroderma in children and adolescents. Rheum Dis Clin North Am 2002; 28: 603-24.
7. Peterson LS, Nelson AM, Su WP, Mason T, O'Fallon WM, Gabril SE. The epidemiology of morphoea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997; 24: 73-80.
8. Marzano AV, Menni S, Parodi A et al. Localized scleroderma in adults and children: clinical and laboratory investigations on 239 cases. Eur J Dermatol 2003; 13: 171-6.
9. Fox TC. Note on the history of scleroderma in England. Br J Dermatol 1892; 4: 101-4.
10. Fagge CH. On keloid scleriasis, morphoea. Guy's Hosp Rep Sev 1868; 3: 255.
11. Klemperer P, Pollack AD, Baehr G. Diffuse collagen disease. Acute lupus erythematosus and diffuse scleroderma. J Am Med Assoc 1942; 119: 331-2.
12. Vancheeswaran R, Black CM, David J et al. Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum 1996; 39: 1041-9.
13. Mosterd K, Winnepenninckx V, Vermeulen A, van Neer PA, van Neer FJ, Frank J. Morphea following surgery and radiotherapy: an evolving problem. J Eur Acad Dermatol Venereol 2009; 23: 1099-101.
14. Torrelo A, Suàrez J, Colmenero I et al. Deep morphea after vaccination in two young children. Pediatr Dermatol 2006; 23: 484-7.
15. Longo F, Saletta S, Lepore L et al. Localized scleroderma after infection with Epstein-Barr virus. Clin Exp Rheumatol 1993; 11: 681-3.
16. Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? [Letter] Lancet 1985; ii: 273.
17. Aberer E, Stanek G. Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am J Dermatopathol 1987; 9: 374-9.
18. Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br J Dermatol 2007; 157: 1189-98.
19. Weide B, Schittek B, Klyscz T et al. Morphoea is neither associated with features of Borrelia burgdorferi infection nor is the agent detectable in lesional skin by polymerase chain reaction. Br J Dermatol 2000; 143: 780-5.
20. Goodlad JR, Davidson MM, Gordon P et al. Morphoea and Borrelia burgdorferi: results from the Scottish Highlands in the context of the world literature. Mol Pathol 2002; 55: 374-8.
21. Zollinger T, Mertz KD, Schmid M, Schmitt A, Pfaltz M, Kempf W. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J Cutan Pathol 2010; 37: 571-7.
22. Burrows NP, Bhogal BS, Russel Jones R, Black MM. Clinicopathological significance of cutaneous epidermal nuclear staining by direct immunofluorescence. J Cutan Pathol 2993; 20: 159-62.
23. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea. A review of 245 adult and pediatric cases. Arch Dermatol 2009; 145: 545-50.
24. Vincent F, Prokopetz R, Miller RA. Plasma cell panniculitis: a unique clinical and pathologic presentation of linear scleroderma. J Am Acad Dermatol 1989; 21: 357-60.
25. Harper JI. Graft versus host disease: etiological and clinical aspects in connective tissue diseases. Semin Dermatol 1985; 4: 144-51.
26. White JM, Creamer D, du Vivier AW et al. Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. Br J Dermatol 2007; 156: 1032-8.
27. Uziel Y, Krafchik BR, Feldman B et al. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 372: 898-901.
28. LeRoy BC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880-9.
29. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology 2009; 48: 213-21.
30. Sato S, Fujimoto M, Kikuchi K et al. Soluble CD4 and CD8 in serum from patients with localized scleroderma. Arch Dermatol Res 1996; 288: 358-62.
31. Sato S, Fujimoto M, Kikuchi K et al. Elevated soluble CD23 levels in the sera from patients with localized scleroderma. Arch Dermatol Res 1996; 288: 74-8.
32. Ihn H, Sato S, Fujimoto M et al. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol 1996; 134: 843-7.
33. Ihn H, Sato S, Fujimoto M et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 28: 193-7.
34. Ihn H, Yazama N, Kubo M et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. J Rheumatol 2000; 27: 698-702.
35. Nagaoka T, Sato S, Hasegawa M et al. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol 2000; 27: 1917-21.
36. Hasegawa M, Sato S, Ngaoka T et al. (2003) Serum levels of tumour necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003; 207, 141-7.
37. Yamane K, Ihn H, Kubo M et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 2000; 42: 64-9.
38. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and Erk1/2 pathways. J Biol Chem 2007; 282: 10405-13.
39. Vuorio T, Kahari VM, Black C et al. Expression of osteonectin, decorin and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991; 18: 247-51.
40. Kubo M, Ihn H, Yamane K et al. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4.
41. Igarashi A, Nashiro K, Kikuchi K et al. Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid and other fibrotic skin disorders. J Invest Dermatol 1996; 106: 729-33.
42. Kreuter A, Hyun J, Skrygan M et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res 2006; 298: 265-72.
43. Fawzi MMT, Tawfik SO, Eissa AM, El-Komy MHM, Abdel-Halim MRE, Shaker OG. Expression of insulin-like growth factor-I in lesional and non-lesional skin of patients with morphoea. Br J Dermatol 2008; 159: 86-90.
44. Iranzo P, Lopez I, Palou J et al. Morphoea in three siblings. J Eur Acad Dermatol Venereol 2001; 15: 46-7.
45. Patrizi A, Marzaduri S, Marini R. A familial case of scleroderma en coup de sabre. Acta Derm Venereol 2000; 80: 237.
46. Brownell I, Soter NA, Franks AG Jr. Familial linear scleroderma (en coup de sabre) responsive to antimalarials and narrowband ultraviolet B therapy. Dermatol Online J 2007; 27: 13-11.
47. Rees RB, Bennett J. Localized scleroderma in father and daughter. Arch Dermatol 1953; 68: 360.
48. Zulian F, Vallongo C, de Oliveira SK et al. Congenital localized scleroderma. J Pediatr 2006; 149: 248-51.
49. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines. Br J Dermatol 2008; 159: 175-81.
50. McNallan KT, Aponte C, el-Azhary R et al. Immunophenotyping of chimeric cells in localized scleroderma. Rheumatology 2007; 46: 398-402.
51. Krieg T, Braun-Falco O, Perlish JS et al. Collagen synthesis in generalized morphea. Arch Dermatol Res 1983; 275: 393-6.
52. Ghersetich I, Teofoli P, Benci M et al. Localized scleroderma. Clin Dermatol 1994; 12: 237-42.
53. Krafchik BR. Localized cutaneous scleroderma. Semin Dermatol 1992; 11: 65-72.
54. Jablonska S. Histopathology of scleroderma. In: Jablonska S, ed. Scleroderma and Pseudoscleroderma. Warsaw: Polish Medical Publishers 1975: 191-233.
55. Krieg T. Skerodermie: Zirkumskripte Sklerodermie. In: Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Landthaler M, eds. Dermatologie und Venerologie, 5th edn. Heidelberg: Springer Verlag, 2005: 676-9.
56. Xie Y, Zhang X, Wakasugi S, Makino T, Inoue Y, Ihn H. Immunohistochemical characterization of the cellular infiltrate in localized scleroderma. Int J Dermatol 2008; 47: 438-42.
57. Zulian F, Martini G. Preliminary classification criteria for juvenile systemic sclerosis. In: Zulian F, Ruperto N, eds. P roceedings of the II Workshop on Nomenclature and Diagnostic Criteria for Juvenile Scleroderma Syndromes; 3-6 June 2004, Padua. Padua: Associazione Il Volo, 2005: 5-16.
58. Weibel L, Sampaio MC, Visentin MT, Howell KJ, Woo P, Harper JI. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Drmatol 2006; 155: 1013-20.
59. Uitto J, Santa Cruz DJ, Bauer EA et al. Morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol 1980; 3: 271-9.
60. Blaya B, Gardeazabal J, de Lagràn ZM, Diaz-Pérez JL. Patient with generalized guttate morphea and lichen sclerosus et atrophicus. Actas Dermosifiliogr 2008; 99: 808-11.
61. Whittaker SJ, Smith NP, Jones RR. Solitary morphoea profunda. Br J Dermatol 1989; 120: 431-40.
62. Person JR, Su WPD. Subcutaneous morphoea: a clinical study of sixteen cases. Br J Dermatol 1979; 100: 371-80.
63. Sommer A, Gambichler T, Bacharach-Buhles M, von Rothenburg T, Altmeyer P, Kreuter A. Clinical and serological characteristics of progressive facial hemiatrophy: a case series of 12 patients. J Am Acad Dermatol 2006; 54: 227-33.
64. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients. J Am Acad Dermatol 2007; 56: 257-63.
65. Stone J. Parry-Romberg syndrome: a global survey of 20 patients using the internet. Neurology 2003; 61: 674-6.
66. Holland KE, Steffes B, Nocton JJ et al. Linear scleroderma en coup de sabre with associated neurologic abnormalities. Pediatrics 2006; 117: 132-136.
67. Chang GY, Park SH, Youn YC, Kwon OS. Neuroimaging findings in scleroderma en coup de sabre. Neurology 2004; 62: 1585-9.
68. Chung MH, Sum J, Morrell MJ, Horoupian DS. Intracerebral involvement in scleroderma en coup de sabre: report of a case with neuropathologic findings. Ann Neurol 1995; 37: 679-81.
69. Unterberger I, Trinka E, Engelhardt K et al. Linear scleroderma'en coup de sabre'coexisting with plaque-morphea: neuroradiological manifestation and response to corticosteroids. J Neurol Neurosurg Psychiatry 2003; 74: 661-4.
70. Neustadter JH, Samarin F, Carlson KR, Girardi M. Extracorporeal photochemotherapy for generalized deep morphea. Arch Dermatol 2009; 145: 127-30.
71. Roldan R, Morote G, Castro Mdel C, Miranda MD, Moreno JC, Collantes E. Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children. J Rheumatol 2007; 34: 1786.
72. Wollina U, Looks A, Uhlemann C, Wollina K. Pansclerotic morphea of childhood follow-up over 6 years. Pediatr Dermatol 1999; 16: 245-7.
73. Roudinesco NN, Vallery-Radot P. Sclérodermie mutilante progressive. Bull Soc Fr Dermatol Syphilol 1923; 30: 151-4.
74. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980; 116: 169-73.
75. Petrov I, Gantcheva M, Miteva L, Vassileva S, Pramatarov K. Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood. Pediatr Dermatol 2009; 26: 59-61.
76. Wollina U, Buslau M, Heinig B et al. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extremity Wounds 2007; 6: 291-8.
77. Birdi N, Laxer RM, Thorner P et al. Localized scleroderma progressing to systemic disease. Case report and review of the literature. Arthritis Rheum 1993; 36: 410-15.
78. Francisco J, Mayorquin TL, McCurley JE et al. Progression of childhood linear scleroderma to fatal systemic sclerosis. J Rheumatol 1994; 21: 1955-7.
79. Hulsmans RFHJ, Asghar SS, Siddiqui AH et al. Hereditary defi-ciency of C2 in association with linear scleroderma'en coup de sabre '. Arch Dermatol 1986; 122: 76-9.
80. Takehara K, Sato S. Localized scleroderma is an autoimmune disease. Rheumatology 2005; 44: 274-279.
81. el Azhary RA, Aponte CC, Nelson AM. Do antihistone autoantibodies reflect disease activity in linear scleroderma? Arch Dermatol 2004; 140: 759-760.
82. Ruffatti A, Peserico A, Glorioso S et al. Anticentromere antibody in localized scleroderma. J Am Acad Dermatol 1986; 15: 637-42.
83. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase II α autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50: 227-32.
84. Grigolo B, Mazzetti I, Borzi RM et al. Mapping of topoisomerase II α autoantibodies in idiopathic pulmonary fibrosis. Clin Exp Immunol 1998; 114: 339-46.
85. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localized scleroderma. Ann Rheum Dis 2003; 62: 771-4.
86. Kikuchi K, Sato S, Kadono T, Ihn H, Takehara K. Serum concentration of procollagen type I carboxyterminal propeptide in localized scleroderma. Arch Dermatol 1994; 130: 1269-72.
87. Uziel Y, Krafchik BR, Feldman B et al. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994; 37: 898-901.
88. Seyger MM, van den Hoogen FH, de Boo T, de Jong EM. Reliability of two methods to assess morphea: skin scoring and the use of a durometer. J Am Acad Dermatol 1997; 37: 793-6.
89. Zulian F, Meneghesso D, Grisan E et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology 2007; 46: 856-60.
90. Arkachaisri T, Vilaiyuk S, Li S et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measues. J Rheumatol 2009; 36: 2819-29.
91. Martini G, Murray KJ, Howell KJ et al. Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology 2002; 41: 1178-82.
92. Birdi N, Shore A, Rush P, Laxer RM, Silverman ED, Krafchik B. Childhood linear scleroderma: a possible role of thermography for evaluation. J Rheumatology 1992; 19: 968-73.
93. Weibel L, Howell KJ, Visentin MT et al. Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum 2007; 56: 3489-95.
94. Seidenari S, Conti A, Pepe P et al. Quantitative description of echographic images of morphoea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings. Acta Dermatol Venereol (Stockh) 1995; 75: 442-5.
95. Cosnes A, Anglade MC, Revuz J et al. Thirteen-megahertz ultrasound probe: its role in diagnosing localized scleroderma. Br J Dermatol 2003; 148: 724-9.
96. Li SC, Liebling MS, Ramji FG et al. Sonographic evaluation of pediatric localized scleroderma: preliminary disease assessment measures. Pediatr Rheumatol Online J 2010; 8: 14.
97. Horger M, Fierlbeck G, Kuemmerle-Deschner et al. MRI findings in deep and generalized morphea. Am J Rheumatol 2008; 190: 32-9.
98. Hess SP, Agudelo CA, White WL et al. Ichthyosiform and morpheaform sarcoidosis. Clin Exp Rheumatol 1990; 8: 171-5.
99. Khelifa E, MasouyéI, Chavaz P, Hauser H, Grillet JP, Borradori L. Primary atrophic solitary morphea profunda. Dermatology 2008; 217: 207-10.
100. Sardana K, Garg VK, Bhushan P, Relhan V Sharma S. DPT vaccine-induced lipoatrophy: an observational study. Int J Dermatol 2007; 46: 1050-4.
101. Holth PJA, Marks R, Waddington E.'Pseudomorphoea ': a side effect of subcutaneous corticosteroid injection. Br J Dermatol 1975; 92: 689-91.
102. Kakimoto CV, Ross EV, Uebelhoer NS. En coup de sabre presenting as a port-wine stain previously treated with pulsed dye laser. Dermatol Surg 2008; 35: 165-7.
103. Quintero-Del-Rio AI, Punaro M, Pasqual V. Faces of eosinophilic fasciitis in childhood. J Clin Rheumatol 2002; 8: 99-103.
104. Assmann A, Mandt N, Geilen CC, Blume-Peytavi U. Buschke-Ollendorff syndrome-differential diagnosis of disseminated connective tissue lesions. Eur J Dermatol 2001; 11: 476-9.
105. Szabo RM, Harris GD, Burke WA. Necrobiosis lipoidica in a 9-year-old girl with new onset type II diabetes mellitus. Pediatr Dermatol 2001; 18: 316-19.
106. Kreuter A, Altmeyer P, Gamblichler T. Treatment of localized scleroderma depends on the clinical subtype. Br J Dermatol 2007; 156: 1363-5.
107. Kroft EB, Groeneveld TJ, Seyer MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphoea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol 2009; 10: 181-7.
108. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153: 815-20.
109. Campione E, Paterno EJ, Diluvio L, Orlandi A, Bianchi L, Chimenti S. Localized morphea treated with imiquimod 5% and dermoscopic assessment of effectiveness. J Dermatolog Treat 2009; 20: 10-3.
110. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1 and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54, 440-7.
111. Ozdemir M, Engin B, Toy H, Mevlitoglu I. Treatment of plaque-type localized scleroderma with retinoic acid and ultraviolet A plus the photosensitizer psoralen: a case series. J Eur Acad Dermatol Venereol 2008; 22: 519-21.
112. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010; 162: 224-7.
113. El-Mofty M, Mostafa W, Esmat S et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 2004; 20: 93-100.
114. Kreuter A, Hyun J, Skrygan M et al. Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res 2006; 298: 265-72.
115. Kreuter A, Gambichler T, Avermaete A et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol 2001; 18: 241-5.
116. Fitch PG, Retting P, Burnham JM et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol 2006; 33: 609-14.
117. Kreuter A, Gambichler T, Breuckmann F et al. Pulsed-high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol 2005; 141: 847-52.
118. Uziel Y, Feldman BM, Krafchik BR et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-5.
119. Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O'Neill KM. Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol 2010; 37: 175-81.
120. Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F. Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatol 2009; 48: 1410-13.
121. Moreno-Romero JA, Fernandez-Aviles F, Carreras E, Rovira M, Martinez C, Mascaro JM Jr. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008; 144: 1106-9.
122. Efficacy and safety of imatinib in scleroderma (SCLEROGLIVEC). An ongoing Phase II randomized double blind clinical trial by the University of Bordeaux. www.clinicaltrials.gov/NCT00479934
123. Black CM. Juvenile scleroderma. In: Woo P, White PH, Ansell BM, eds. Paediatric Rheumatology Update. Oxford: Oxford University Press, 1990: 194-208.
124. Buckley SL, Skinner S, James P et al. Focal scleroderma in children: an orthopaedic perspective. J Pediatr Orthop 1993; 13: 784-90.